GRI Bio Participates in a Virtual Investor CEO Connect Segment
Access the CEO Connect segment hereLA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a ...
Yahoo Finance7d
GRI Bio, Inc. (GRI)
LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ...
Nasdaq11d
GRI Bio, Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule
GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that it has regained compliance with ...
GRI Bio expects cash to fund operations into Q2 of 2025
As of December 31, 2024, the Company had cash and cash equivalents of approximately $5.0 million. Based on the Company’s current operating ...
The National Law Review26d
GRI Bio Announces Reverse Stock Split
LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ...
WRIC1mon
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ...
Nasdaq1mon
GRI Bio, Inc. Highlights Key Investment Reasons at Virtual Investor Conference
GRI Bio, Inc. announced its participation in the Virtual Investor "Top 5 for '25" On-Demand Conference, where CEO Marc Hertz, Ph.D., presented compelling reasons for investors to pay attention to ...
Morningstar4d
GRI Bio Participates in a Virtual Investor CEO Connect Segment
LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ...